Drug intelligence / Profile preview

SIT-052

Development stage: Unknown
Lead developer: Sitryx
Modality: Small Molecules
Administration: Oral

Overview

SIT-052 is an oral small molecule developed by Sitryx, functioning as a first-in-class glutaminase 1 (GLS1) inhibitor. This drug candidate is designed to attenuate autoimmune responses, particularly those associated with atopic diseases such as moderate to severe allergic asthma. Preclinical studies have demonstrated its ability to control disease in various inflammatory and autoimmune models, suggesting its potential as an oral treatment offering biologic-like disease control.

Targets

GLS1 (Glutaminase 1)

Beyond the preview

Go deeper on SIT-052.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIT-052.

Explore the full profile